FDA Issues Final Guidance on Prescription Drug Apps and Software
The US Food and Drug Administration has released final guidance to establish a regulatory framework for how pharmaceutical companies develop, distribute, and label apps used with prescription medications.
The guidance clarifies when app content requires FDA submission, when it should be referenced on official drug labels, and how to distinguish between FDA-required labeling and promotional material. It categorizes companion software into apps connected to medical devices, which should generally appear on official prescribing information, and standalone apps, which require inclusion on the label if they are essential for safe and effective use or show meaningful clinical benefit.
Key points
- Final guidance establishes a framework for prescription drug apps and software.
- Addresses when app content is treated as FDA-required labeling versus promotional material.
- Apps connected to medical devices should generally be described on the drug's official prescribing label.
- Standalone apps require label inclusion if they are essential for safe and effective use or show clinical benefit.
What it means for you
This FDA guidance clarifies regulatory standards for digital health tools used alongside medications, ensuring that app information provided to patients and providers is accurate and evidence-based. Clinicians and pharmacists in Pakistan should note that this is a US regulatory update and check with the Drug Regulatory Authority of Pakistan (DRAP) for any local guidelines concerning digital health tools and drug software.
FDA Issues Final Guidance on Prescription Drug Apps and Software
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.